Collaborations and publications are strong proofs of the relevance of our research.

Dr. Laurent Meijer: H-Factor (81), ResearchGate score: 48.93

Cystic Fibrosis (CF)

  1. Meijer, L., Hery-Arnaud, G., Leven, C., Nowak, E., Hillion, S., Renaudineau, Y., Durieu, I., Chiron, R., Prévotat, A., Fajac, I., Hubert, D., Muris-Espin, M., Huge, S., Danner-Boucher, I., Ravoninjatovo, B., Leroy, S., Macey, J., Urban, T., Rault, G., Mottier, D. and Le Berre, R., 2021. Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study. J. Cystic Fibrosis, submitted July 14, 2021.
  2. Leven, C., Schutz, S., Audrezet, M.P., Nowak, E., Meijer, L. and Montier, T., 2020. Non-linear pharmacokinetics of oral Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa: a population pharmacokinetics study with Monte Carlo simulations. Pharmaceutics 12, 1087.
  3. Marteyn, B.S., Burgel, P.R., Meijer, L. and Witko-Sarsat, V., 2017. Harnessing neutrophil survival mechanisms during chronic infection by Pseudomonas aeruginosa: novel therapeutic targets to dampen inflammation in cystic fibrosis. Front. Cell. Infect. Microbiol. 7, 243.
  4. Meijer, L., Nelson, D., Riazanski, V., Gabdoulkhakova, A.G., Hery-Arnaud, G., Leberre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., Gueganton, L., Dorothée, G., Prochazkova, M., Hall, B., Kulkarni, A.B., Gray, R.D., Rossi, A.G., Witko-Sarsat, V., Norez, C., Becq, F., Ravel, D., Mottier, D. and Rault, G., 2016. Modulating innate and adaptative immunity by (R)-roscovitine: potential therapeutic opportunity in cystic fibrosis J. Innate Immunity 8, 330-349.
  5. Riazanski, V., Gabdulkhakova, A.G., Boynton, L.S., Eguchi, R.R., Deriy, L.V., Hogarth, D.K., Loaëc, N., Oumata, N., Galons, H., Brown, M.E., Shevchenko, P., Gallan, A.J., Yoo, S.G., Naren, A.P., Villereal, M.L., Beacham, D.W., Bindokas, V.P., Birnbaumer, L., Meijer, L. and Nelson, D.J., 2015. TRPC6 channel translocation into phagosomal membrane augments phagosomal function. Proc. Natl. Acad. Sci. USA 112, E6486-6495.
  6. A Phase II, dose ranging, multicenter, double-blind, placebo controlled study to evaluate safety and effects of (R)-roscovitine in subjects with Cystic Fibrosis, homozygous for the F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa, a study involving 36 CF patients (24 treated, 12 controls). ANSM authorization Sept. 15, 2015.
  7. Norez, C., Vandebrouck, C., Bertrand, J., Noel, S., Durieu, E., Oumata, N., Galons, H., Antigny, F., Chatelier, A., Bois, P., Meijer, L. and Becq, F., 2014. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. Br. J. Pharmacol. 171, 4831-4849.